Literature DB >> 32007842

Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation.

Ashly E Jordan1, David C Perlman2, Charles M Cleland3, Katarzyna Wyka4, Bruce R Schackman5, Denis Nash4.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) infection is the most prevalent blood-borne infection and causes more deaths than any other infectious disease in the US. Incident HCV infection in the US increased nearly 300 % between 2010 and 2015, Community viral load (CVL) measures have been developed for HIV to measure both transmission risk and treatment engagement in programs or areas.
OBJECTIVE: This paper presents a systematic review exploring the published literature on CVL constructs applied to HCV epidemiology and proposes novel CVL measures for HCV. STUDY DESIGN AND
SETTING: A systematic review was conducted of electronic databases; the search sought to identify published literature on HCV which discussed or applied CVL measures to HCV epidemiology. Novel CVL measures were constructed to apply to HCV.
RESULTS: No reports examining quantitative measures of HCV CVL were identified. Using the HIV CVL literature and the specific characteristics of HCV epidemiology, five HCV CVL measures are proposed. Narrower measures focusing on those engaged-in-care may be useful for program evaluation and broader measures including undiagnosed people may be useful for surveillance of HCV transmission potential.
CONCLUSION: Despite their potential value, CVL constructs have not yet formally been developed and applied to HCV epidemiology. The CVL measures proposed here could serve as valuable HCV program and surveillance measures. There is a need for informative surveillance measures to enhance policy and public health responses to achieve HCV control. Further study of these proposed HCV CVL measures to HCV epidemiology is warranted.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Community viral load; Hepatitis C control; Hepatitis C surveillance; Hepatitis C virus; Novel epidemiologic measures; Systematic review

Mesh:

Year:  2020        PMID: 32007842      PMCID: PMC7195813          DOI: 10.1016/j.jcv.2020.104285

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  75 in total

1.  An international registry of systematic-review protocols.

Authors:  Alison Booth; Mike Clarke; Davina Ghersi; David Moher; Mark Petticrew; Lesley Stewart
Journal:  Lancet       Date:  2010-07-12       Impact factor: 79.321

2.  Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study.

Authors:  Jemima A Frimpong; Thomas D'Aunno; Lan Jiang
Journal:  Am J Public Health       Date:  2014-04-17       Impact factor: 9.308

3.  Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in Canada.

Authors:  Sergio M Borgia; Adenike Rowaiye
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04

4.  Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients.

Authors:  Rachel Eren; Dorit Landstein; Dov Terkieltaub; Ofer Nussbaum; Arie Zauberman; Judith Ben-Porath; Judith Gopher; Rachel Buchnick; Riva Kovjazin; Ziva Rosenthal-Galili; Sigal Aviel; Ehud Ilan; Yariv Shoshany; Lewis Neville; Tal Waisman; Ofer Ben-Moshe; Alberto Kischitsky; Steven K H Foung; Zhen-Yong Keck; Orit Pappo; Ahmed Eid; Oded Jurim; Gidi Zamir; Eithan Galun; Shlomo Dagan
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

5.  Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C.

Authors:  L E Adinolfi; R Utili; A Andreana; M F Tripodi; M Marracino; M Gambardella; M Giordano; G Ruggiero
Journal:  Dig Dis Sci       Date:  2001-08       Impact factor: 3.199

6.  Where science meets policy: comparing longitudinal and cross-sectional designs to address diarrhoeal disease burden in the developing world.

Authors:  Amanda R Markovitz; Jason E Goldstick; Karen Levy; William Cevallos; Bhramar Mukherjee; James A Trostle; Joseph N S Eisenberg
Journal:  Int J Epidemiol       Date:  2012-01-09       Impact factor: 7.196

7.  Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011.

Authors:  Claire L Townsend; Laura Byrne; Mario Cortina-Borja; Claire Thorne; Annemiek de Ruiter; Hermione Lyall; Graham P Taylor; Catherine S Peckham; Pat A Tookey
Journal:  AIDS       Date:  2014-04-24       Impact factor: 4.177

8.  Risk factors for HCV infection among young adults in rural New York who inject prescription opioid analgesics.

Authors:  Jon E Zibbell; Rachel Hart-Malloy; John Barry; Lillian Fan; Colleen Flanigan
Journal:  Am J Public Health       Date:  2014-09-11       Impact factor: 9.308

9.  Report from the International Viral Hepatitis Elimination Meeting (IVHEM), 17-18 November 2017, Amsterdam, the Netherlands: gaps and challenges in the WHO 2030 hepatitis C elimination framework.

Authors:  Stephanie Popping; Manal El-Sayed; Jordan Feld; Angelos Hatzakis; Margaret Hellard; Olufunmilayo Lesi; Michael Ninburg; John Ward; Charles Boucher
Journal:  J Virus Erad       Date:  2018-07-01

10.  State HCV Incidence and Policies Related to HCV Preventive and Treatment Services for Persons Who Inject Drugs - United States, 2015-2016.

Authors:  Cecily A Campbell; Lauren Canary; Nicole Smith; Eyasu Teshale; A Blythe Ryerson; John W Ward
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-05-12       Impact factor: 17.586

View more
  1 in total

1.  COVID-19 and People Who Use Drugs - A Commentary.

Authors:  Suzan M Walters; David W Seal; Thomas J Stopka; Megan E Murphy; Wiley D Jenkins
Journal:  Health Behav Policy Rev       Date:  2020-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.